• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Darzalex Regimen May Improve MRD Responses in Multiple Myeloma

by | Dec 21, 2024 | Uncategorized

Source: CureToday articles Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination. Read More

Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey

by | Dec 17, 2024 | Uncategorized

Source: CureToday articles Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®. Read More

Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma

by | Dec 10, 2024 | Uncategorized

Source: CureToday articles Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition. Read More

Tecvayli Effective Maintenance Therapy in Newly Diagnosed Multiple Myeloma

by | Dec 9, 2024 | Uncategorized

Source: CureToday articles Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates. Read More

Darzalex Faspro May Improve Progression, Survival in Smoldering Multiple Myeloma

by | Dec 9, 2024 | Uncategorized

Source: CureToday articles The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma. Read More

Daratumumab superior to active monitoring for high-risk smoldering multiple myeloma

by | Dec 8, 2024 | Uncategorized

SAN DIEGO — Daratumumab monotherapy significantly delayed progression of high-risk smoldering multiple myeloma to active multiple myeloma compared with active monitoring, according to results of the randomized phase 3 AQUILA study.Daratumumab (Darzalex, Janssen)...
« Older Entries
Next Entries »

Recent Content

  • Analysis Reveals Polypharmacy Challenges in Patients With Cancer
  • Trastuzumab Deruxtecan Plus Pertuzumab Improves Progression-Free Survival in Patients With HER2+ Metastatic Breast Cancer
  • Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer
  • My 11-Year Metastatic Breast Cancer Story Defied the Standard Path
  • A Step Forward: Optimizing the Delivery of Pegaspargase Therapy in Adult Patients With ALL
  • Migraine With Aura Plays Most Prominent Role in Women With Young-Onset CIS
  • Antibiotic Use in Infants and Young Children May Increase Risk of Allergic Conditions
  • Training and Education Ensure Safe Handling of Hazardous Drugs
  • NCPA Report Outlines Potential Negative Impacts of MDPNP, Solutions
  • FAERS Analysis Provides New Insights on Cefiderocol Adverse Effects
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT